BuybackAug 12, 2026, 07:38 AM
Arbutus Plans $230M Share Buyback; Q2 Net Loss $5.1M
AI Summary
Arbutus Biopharma reported a Q2 2026 net loss of $5.1 million, or $0.03 per share, compared to a net income of $2.5 million in Q2 2025. The company received $178.4 million from the Moderna settlement and plans to return up to $230 million in capital to shareholders through repurchases. Arbutus also filed three international patent enforcement lawsuits against Pfizer and BioNTech and achieved FDA alignment for its imdusiran Phase 2b clinical trial.
Key Highlights
- Received $178.4M from Moderna settlement in July 2026.
- Plans to return up to $230M in capital to shareholders via share repurchases.
- Filed three international patent lawsuits against Pfizer and BioNTech over LNP technology.
- Achieved FDA alignment on imdusiran Phase 2b clinical trial design.
- Q2 2026 net loss was $5.1M ($0.03/share) vs. net income of $2.5M in Q2 2025.
- Total revenue for Q2 2026 was $1.0M, down from $10.7M in Q2 2025.
- Cash, cash equivalents, and marketable securities were $92.6M as of June 30, 2026.
- R&D expenses decreased to $2.9M in Q2 2026 from $5.5M in Q2 2025.
Price Impact
More from ABUS